Interestingly, patients receiving anti-PD-1 or anti PD-L1 immune checkpoint inhibitors for cancer therapy have been shown to spontaneously develop rheumatoid arthritis [61] suggesting these pathways have a role in controlling joint inflammation. The gene discussed is CD274; the disease is rheumatoid arthritis.